Current status and future of clinical islet Xenotransplantation 临床异种胰岛移植的现状与将来
详细信息 查看全文
- 作者：Shinichi Matsumoto ; Masayuki Tomiya and Osamu Sawamoto
- 刊名：Journal of Diabetes
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：8
- 期：4
- 页码：483-493
- 全文大小：358K
- ISSN：1753-0407
文摘
β-Cell replacement therapy, including allogeneic pancreas and islet transplantation, can normalize HbA1c levels in unstable type 1 diabetic (T1D) patients, but a donor shortage is a serious issue. To overcome this problem, xenotransplantation is an attractive option. In fact, islet transplantation from porcine pancreata was performed in the 1990s, which opened the door for islet xenotransplantation, but the possibility of porcine endogenous retrovirus (PERV) infection was raised, which has restricted progress in this field. The International Xenotransplantation Association published a consensus statement on conditions for undertaking clinical trials of porcine islet products in T1D to restart islet xenotransplantation safely. Clinical porcine islet xenotransplantation was restarted under comprehensive regulations in New Zealand. In addition, newly emerged gene-editing technologies have activated the xenotransplantation field. Islet xenotransplantation is becoming a clinical reality, with the results of recent studies showing promise to advance this field.